Gets a Neutral rating from RBC ZD 12:28am French and Benelux stocks-Factors to watch RE Oct. 15 Sanofi Signs Letter of Intent With Canadian Drug Alliance for Dupixent in Four Additional Indications MT ...
Phase-1-Studien sind für 2027 geplant. Die Sanofi-Aktie kostet am 16.10.2026 71,56 Euro, 1,16 Prozent unter dem Xetra-Schluss ...
【財華社訊】北京時間2026年10月16日晚間，美股周五早盤，知名美股跌幅榜前十名分別為Recursion Pharmaceuticals, Inc. Class A(RXRX.US)跌幅7.09%、RYTHM, Inc.(RYM.US)跌幅7.01%、Cloudflare Inc Class A(NET.US)跌幅5.44%、Datadog, Inc. Class A(DDOG.US)跌幅4.7 ...
In his latest research note, analyst Trung Huynh confirms his recommendation. The broker RBC is keeping its Neutral rating. The target price is lowered from EUR 80 to EUR 75.
22nd Century Group Inc. XXII shares jumped 64.22% to $1.03 in after-hours trading on Thursday, after the company reported a ...
Report Tracks Roche Diagnostics, Thermo Fisher, Illumina, Agilent and Guardant Health Among 132 Companies, With Forecasts by Assay Type, Technology, Customer and CountryDublin, Oct. 16, 2026 (GLOBE ...
Les actions de Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) sont en hausse vendredi. Les actions de la société de biotechnologie en phase clinique basée ...
12hon MSN
Recursion Pharmaceuticals (RXRX) stock is trending after hours: Here’s what you should know
Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...
Sanofi übernimmt Finanzierung und Leitung des Kandidaten; der Start einer Phase-1-Studie ist für 2027 vorgesehen.
【財華社訊】北京時間2026年10月16日淩晨，美股周四收盤，知名美股漲幅榜前十名分別為愛立信(ERIC.US)漲幅+11.80%、Recursion Pharmaceuticals, Inc. Class A(RXRX.US)漲幅+11.23%、美國先鋒(AVD.US)漲幅+10.62%、Compass Inc Class A(COMP.US)漲幅+9.82%、ZipRecruiter, Inc ...
Recursion Pharmaceuticals ha anunciado que Sanofi ha ejercido la opción sobre el primer candidato de desarrollo surgido de la ...
Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results